FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer

被引:42
|
作者
Akita, H. [1 ]
Takahashi, H. [1 ]
Ohigashi, H. [2 ]
Tomokuni, A. [1 ]
Kobayashi, S. [1 ]
Sugimura, K. [1 ]
Miyoshi, N. [1 ]
Moon, J. -H. [1 ]
Yasui, M. [1 ]
Omori, T. [1 ]
Miyata, H. [1 ]
Ohue, M. [1 ]
Fujiwara, Y. [1 ]
Yano, M. [1 ]
Ishikawa, O. [1 ]
Sakon, M. [1 ]
机构
[1] Osaka Med Ctr Canc & Cardiovasc Dis OMCC, Dept Surg, Osaka, Japan
[2] Saiseikai Senri Hosp, Dept Surg, Suita, Osaka, Japan
来源
EJSO | 2017年 / 43卷 / 06期
关键词
Pancreatic cancer; Neoadjuvant; Chemoradiotherapy; FDG-PET; POSITRON-EMISSION-TOMOGRAPHY; GEMCITABINE-BASED CHEMORADIATION; PATHOLOGICAL RESPONSE; ADENOCARCINOMA; SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY; RECURRENCE; PACLITAXEL; MANAGEMENT;
D O I
10.1016/j.ejso.2017.03.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The efficacy of neoadjuvant chemoradiotherapy (NACRT) for resectable and borderline resectable pancreatic cancer is important for predicting outcomes after radical surgery, but few clinical indicators predict outcome before resection. This study examined the utility of FDG-PET in predicting the efficacy of NACRT and outcome after radical surgery. Methods: Eighty-three pancreatic cancer patients who underwent FDG-PET before and after NACRT and had positive standard uptake values (SUVs) before NACRT were enrolled in this study. Peri-operative clinical factors, including FDG-PET findings, were examined to predict the efficacy of NACRT and outcome after surgery. Results: Evans grade I, IIA, [03, III, and IV was determined in 11, 31, 27, 11, and 3 patients, respectively. The maximum SUVs after NACRT (post SUV-max) and tumor size were significantly decreased compared to pretreatment values (p < 0.001 and p = 0.007, respectively). The post SUV-max and regression index were significantly related to grade III/IV (p = 0.04 and p < 0.001, respectively), but only the regression index predicted NACRT efficacy (p = 0.002). The AUC of the regression index for the detection of grade III/IV was 0.822, and 13 of 14 grade lII/IV patients were picked up using 50% as the threshold (p < 0.001). Patients with a regression index >50% had a significantly better prognosis after radical resection than patients with <50% (p = 0.032). Regression index as well as pathological lymph node status and resectability status were independent prognostic factors in multivariate analysis (exp 2.086, p = 0.043). Conclusion: The regression index is potentially a good indicator of the efficacy of NACRT and outcome after radical resection for pancreatic cancer. (C) 2017 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:1061 / 1067
页数:7
相关论文
共 50 条
  • [21] Advances in Non-surgical Treatment for Borderline Resectable Pancreatic Cancer
    Sudo, K.
    Tsujimoto, A.
    Takayama, W.
    Nakamura, K.
    Kita, E.
    Ishii, H.
    Yamaguchi, T.
    PANCREAS, 2019, 48 (10) : 1528 - 1528
  • [22] The use of FDG-PET/CT in the pre-operative staging of pancreatic ductal adenocarcinoma
    Jordan, Rebecca
    Muir, Duncan
    van Laarhoven, Stijn
    Falk, Stephen
    Strickland, Andrew
    Skipworth, James
    BRITISH JOURNAL OF SURGERY, 2021, 108
  • [23] Circulating Tumor DNA to Predict Surgical Outcome after Neoadjuvant Chemoradiation for Borderline Resectable/Locally Advanced Pancreatic Cancer
    McDuff, S.
    Parikh, A. S.
    Hazar-Rethinam, M.
    Zheng, H.
    Van Seventer, E.
    Nadres, B.
    Lennerz, J. K.
    Ryan, D. P.
    Weekes, C.
    Clark, J. W.
    Fernandez-del Casti, C.
    Ferrone, C. R.
    Lillemoe, K.
    Goyal, L.
    Zhu, A. X.
    Wo, J. Y.
    Blaszkowsky, L. S.
    Allen, J. N.
    Corcoran, R.
    Hong, T. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S134 - S134
  • [24] Pre-Operative Circulating Tumour DNA (ctDNA) Predicts Outcome in Resectable Stage III Melanoma
    Lee, J. H.
    Saw, R. P. M.
    Lo, S.
    Thompson, J. F.
    Spillane, A. J.
    Kerwin, S.
    Stretch, J.
    Howle, J.
    Guminski, A.
    Menzies, A. M.
    Carlino, M. S.
    Kefford, R.
    Scolyer, R. A.
    Long, G. V.
    Rizos, H.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 52 - 52
  • [25] Pre-operative Staging of Lung Cancer The Role of FDG-PET CT
    Amthauer, H.
    PNEUMOLOGE, 2010, 7 (01): : 43 - +
  • [26] Complications of pre-operative biliary drainage do not adversely impact post surgical outcomes in resectable pancreatic cancer
    Yoganathan, P.
    Bassan, M. S.
    Volovets, A.
    Hanna, M.
    Pavey, D.
    Chang, D.
    Koo, J. H.
    Biankin, A.
    Edwards, P. D.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 38 - 39
  • [27] RANDOMIZED MULTICENTER STUDY OF NEOADJUVANT CHEMORADIATION THERAPY (CRT) ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RESECTABLE OR BORDERLINE RESECTABLE PANCREATIC CANCER
    Rahma, Osama
    Katz, Mathew
    Bauer, Todd
    Wolpin, Brian
    Stucky, Chee-Chee
    Bekaii-Saab, Tanios
    Elias, Rawad
    Dias-Costa, Andressa
    Nowak, Jonathan
    Patrick, Lenehan
    Petroni, Gina
    Dougan, Stephanie
    Slingluff, Craig
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A1010 - A1010
  • [28] Surgical Treatment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement by Evans et al.
    Reid B. Adams
    Peter J. Allen
    Annals of Surgical Oncology, 2009, 16 : 1745 - 1750
  • [29] Current Surgical Concepts and Future Perspectives in the Treatment of Borderline Resectable and Potentially Resectable Locally Advanced Pancreatic Cancer
    Karamarkovic, Aleksandar R.
    Juloski, Jovan T.
    CHIRURGIA, 2022, 117 (04) : 385 - 398
  • [30] Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer
    Bryan J. Schneider
    Julia Shin-Jung Lee
    James A. Hayman
    Andrew C. Chang
    Mark B. Orringer
    Allan Pickens
    Charlie C. Pan
    Sofia D. Merajver
    Susan G. Urba
    Investigational New Drugs, 2013, 31 : 435 - 442